SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (221)9/21/1997 7:07:00 AM
From: David Cathcart   of 1826
 
MZ

It is unclear to me why you say that - relative to adding a second phase I trial -- it would save time to expand the current phase I trials with a slightly changed protocol. The second phase I trial begins at the highest current rate in the ongoing phase I trial, so where is the delay? It is important to note that the second phase I trials does not repeat the lower dose levels of the first trial. With two phase I trials progressing concurrently at the same dose level, but with slightly different protocols, you are able to move through more patients. More patients will result in more data. There also may be some unforeseen value in having two separate protocols. Go back and read Richard Dean Bagnell's September 15th post (#200). I think he is right.

Certainly, MGI 114 has a long way to go before it can become a major cancer therapy. Many questions remain to be answered and that will take time. While I wish MGI Pharma would be more forthcoming with current information from the clinical trials, my sense is that the company knows what it is doing with MGI 114. If the drug works, the rewards will be huge. While we are waiting to find out, focus on the bang-for-your-buck that you will get from Salagen. They know what they are doing with that drug too and "the Salagen surge" is close at hand.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News